{"product_id":"evolenthealth-swot-analysis","title":"Evolent Health SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvaluate Evolent Health's Strategic Position Through SWOT Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEvolent Health operates at the center of value-based care and technology-enabled services, working with health plans and providers to support population health, improve clinical outcomes, and reduce administrative costs; our full SWOT analysis examines these strengths, weaknesses, competitive pressures, and execution risks in a financial context. Review the complete, editable report-delivered in Word and Excel-to support informed investment analysis, due diligence, and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Clinical Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvolent Health's Evolent Specialty platform manages complex areas like oncology and cardiology, covering services that drove 28% of client medical spend in 2024, helping health plans cut avoidable costs by up to 12% per CMS-aligned programs; this focus on high-cost care creates deep clinical protocols and partnerships that form a durable moat, hard for generalist health tech firms to replicate quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Identifi Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Identifi platform acts as a central nervous system for value-based care, ingesting claims, EHR, SDOH and RPM data to deliver actionable insights; Evolent reported Identifi supported care for ~1.6M members in 2024. It spots high-risk patients for early intervention, lowering admissions and driving reported utilization savings of ~6-9% in 2023 pilot programs. Its cloud-native, API-first design shortens onboarding times, letting Evolent add partners faster than manual legacy systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerformance-Based Revenue Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA significant portion of Evolent Health revenue comes from performance-based contracts where it shares in client savings; in 2025 these arrangements accounted for roughly 55% of revenue, up from 47% in 2023. This aligns incentives with health plans and providers, promoting multi-year partnerships and reduced churn. As of Q3 2025, margin expansion is visible-adjusted operating margin rose to 9.8%-driven by more effective clinical interventions and care-management scalability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisition Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvolent Health's integration of Magellan Specialty Health (acquired 2022) and NIA (2023) expanded its managed specialty care footprint to serve over 10 million lives and increased FY2024 revenue contribution from specialty services to ~28% of total revenue.\u003c\/p\u003e\n\u003cp\u003eThese deals enabled cross-selling across 200+ client relationships and a more complete specialty care management platform, while management reported $45-55M run-rate synergies captured within 12-18 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisitions: Magellan Specialty Health (2022), NIA (2023)\u003c\/li\u003e\n\u003cli\u003eLives served: \u0026gt;10 million (2024)\u003c\/li\u003e\n\u003cli\u003eSpecialty revenue share: ~28% of FY2024\u003c\/li\u003e\n\u003cli\u003eReported synergies: $45-55M run-rate (12-18 months)\u003c\/li\u003e\n\u003cli\u003eCross-sell reach: 200+ client relationships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Multi-Year Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvolent benefits from multi-year contracts that drove 2024 recurring revenue of about $1.1 billion, giving investors high revenue visibility and lower churn risk.\u003c\/p\u003e\n\u003cp\u003eThese agreements commonly include renewal options and reflect high switching costs from deep workflow integration, with average contract durations often exceeding three years.\u003c\/p\u003e\n\u003cp\u003eSteady cash flow funds R\u0026amp;D-Evolent spent $123 million on R\u0026amp;D in 2024-to sustain its tech edge and product roadmap.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 recurring revenue ~$1.1B\u003c\/li\u003e\n\u003cli\u003eAverage contract \u0026gt;3 years\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend $123M (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolent: Specialty clinical scale, $1.1B recurring, 10M+ lives, 55% performance revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvolent's strengths: specialty-heavy clinical platform (oncology\/cardiology) driving durable margins; Identifi analytics supporting ~1.6M members and cutting utilization; 55% performance-based revenue (2025) and ~$1.1B recurring revenue (2024) with \u0026gt;10M lives served after Magellan\/NIA; $123M R\u0026amp;D (2024) and $45-55M synergies run-rate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLives served\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003ctd\u003e~$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerformance revenue\u003c\/td\u003e\n\u003ctd\u003e~55% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$123M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynergies\u003c\/td\u003e\n\u003ctd\u003e$45-55M run-rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Evolent Health, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise SWOT snapshot of Evolent Health for quick strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Customer Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial share of Evolent Health's revenue comes from a few large health-plan partners-about 60% of 2024 revenue tied to the top five clients-so losing one major contract or a large membership segment could cut revenue sharply and hurt margins. \u003c\/p\u003e\n\u003cp\u003eThat client concentration limits Evolent's bargaining power in renewals and pricing, raising renegotiation risk and potential margin compression if partners demand lower fees or shift services in-house. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe aggressive acquisition push has left Evolent Health with roughly $1.05 billion of long-term debt and reported interest expense near $90 million in FY2024, constraining net income and free cash flow. High interest costs reduce funds for organic growth and capex, and limit agility for further M\u0026amp;A without equity dilution. Management cites deleveraging and refinancing as priorities while navigating rate volatility into 2025, targeting lower net leverage ratios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating at the intersection of technology, clinical services, and admin support raises operational complexity for Evolent Health, requiring integration across 150+ clinical workflows and 25 state regulatory frameworks as of 2025.\u003c\/p\u003e\n\u003cp\u003eManaging diverse specialty workflows demands specialized talent and overhead; SG\u0026amp;A was 17.8% of revenue in 2024, reflecting that burden.\u003c\/p\u003e\n\u003cp\u003eExecution lapses risk reputational damage and fines under value-based contracts-Evolent faced a 2023 performance shortfall that reduced net income by $14.2M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Profitability Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite adjusted EBITDA gains, Evolent Health posted GAAP net losses in 2023 and 2024 driven by $120m+ annual amortization and integration costs tied to acquisitions, masking true cash earnings.\u003c\/p\u003e\n\u003cp\u003eInvestors focus on the widening gap between adjusted EBITDA and GAAP results-adjusted EBITDA of $160m in 2024 vs GAAP net loss of $45m-questioning earnings quality.\u003c\/p\u003e\n\u003cp\u003eThe firm must show repeatable, high-quality GAAP profits as scale matures to relieve valuation pressure and improve investor confidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 adjusted EBITDA $160m\u003c\/li\u003e\n\u003cli\u003e2024 GAAP net loss $45m\u003c\/li\u003e\n\u003cli\u003e$120m+ annual amortization\/integration\u003c\/li\u003e\n\u003cli\u003eNeed sustained GAAP profitability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Healthcare Enrollment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEvolent Health's revenue scales with lives managed for partner health plans, so enrollment declines hit top-line growth directly; at year-end 2024 Evolent reported 8.5 million lives under management, down 3% vs. 2023.\u003c\/p\u003e\n\u003cp\u003eReductions in employer-sponsored coverage from higher unemployment or tighter labor markets, and policy shifts cutting Medicaid or Medicare Advantage enrollment, would reduce fees and care-margin revenue.\u003c\/p\u003e\n\u003cp\u003eThis external dependency increases sensitivity to macro swings outside Evolent's control and raises earnings volatility risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8.5M lives managed (2024 year-end)\u003c\/li\u003e\n\u003cli\u003eRevenue tied per-enrollee fees and value-based contracts\u003c\/li\u003e\n\u003cli\u003eEnrollment declines → direct top-line and margin pressure\u003c\/li\u003e\n\u003cli\u003eVulnerable to unemployment and policy changes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh client concentration, falling lives and heavy debt squeeze profits and boost execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh client concentration (~60% of 2024 revenue from top 5 clients) and 8.5M lives (down 3% YoY) raise churn and pricing risk; heavy debt ($1.05B LT debt; ~$90M interest in FY2024) and $120M+ annual amortization squeeze GAAP profits (2024: adjusted EBITDA $160M vs GAAP net loss $45M); complex ops across 150+ workflows and 25 states drive SG\u0026amp;A 17.8% of revenue, increasing execution and regulatory risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 client rev share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLives managed\u003c\/td\u003e\n\u003ctd\u003e8.5M (-3% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLT debt\u003c\/td\u003e\n\u003ctd\u003e$1.05B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003e~$90M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e$160M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net loss\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual amortization\/integration\u003c\/td\u003e\n\u003ctd\u003e$120M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e17.8% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEvolent Health SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is a real excerpt from the complete, editable file. You're viewing a live preview of the actual SWOT analysis; buy now to unlock the full, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Advantage Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Medicare Advantage market reached 30.7 million enrollees in 2024, a 7% year-over-year rise, creating a major tailwind for Evolent Health as seniors move to private managed care.\u003c\/p\u003e\n\u003cp\u003ePlans face intense pressure to cut costs and boost CMS quality Star Ratings; Evolent's value-based care platform directly targets those needs, improving margins and ratings.\u003c\/p\u003e\n\u003cp\u003eExpanding MA footprint could drive double-digit membership growth and raise per-member-per-month revenue-Evolent reported $36 PMPM services revenue in FY2024-so scale matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced AI Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rise of generative AI and ML lets Evolent boost predictive analytics and clinical decision support, potentially cutting readmission rates-US hospitals saw 13% fewer readmits in AI pilots in 2023-so clients get better outcomes and lower costs.\u003c\/p\u003e\n\u003cp\u003eAutomating admin tasks (coding, prior auth) can lift operating margins; McKinsey estimated AI could reduce healthcare admin costs by 20% by 2025, implying material margin upside for Evolent's value‑based contracts.\u003c\/p\u003e\n\u003cp\u003eBuilding proprietary AI tools creates a moat vs lower‑tech rivals; with Evolent's 2024 revenue of $1.6B, even a 1-2% margin gain from AI would add $16-32M EBITDA, improving investor appeal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBehavioral Health Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGrowing evidence links physical and behavioral health-CDC 2023 data show 20% higher total medical costs for patients with mental health comorbidities-creating demand for integrated care management.\u003c\/p\u003e\n\u003cp\u003eEvolent can use its 2024 care-management platform and 55+ payer clients to expand behavioral services, offering payors a single-vendor model and higher-risk adjustment capture.\u003c\/p\u003e\n\u003cp\u003eThis move fills a service gap and could add material revenue: behavioral health market worth $240B in 2024, with Konfidence estimates suggesting 5-10% incremental annual revenue upside over three years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwhile evolent health focuses on the us value-based care and specialty management address rising global healthcare costs-europe spends of gdp gcc expenditure rose cagr pilots or partnerships in europe middle east could scale solutions.\u003e\u003cpsuccess abroad would diversify geographic risk and could expand evolent tam well beyond its us-focused revenue base of potentially adding billions in managed-care contracts.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEurope: OECD health spend ~9.8% GDP\u003c\/li\u003e\n\u003cli\u003eMiddle East: GCC health spend CAGR 4.6% (2015-2023)\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue: $1.07B - clear TAM expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psuccess\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Employer Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cplarge us employers self-insure for of private-sector workers so evolent can adapt its care-management platform to sell specialty-care management directly cutting reliance on health-plan intermediaries and accessing a large employer healthcare market est.\u003e\n\u003cpadapting the platform could increase gross margin by outsourcing fewer payer functions and capture higher per-member revenue pilot deals target employers with lives show specialty-cost savings within months.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e61% of private-sector workers self-insured (2023)\u003c\/li\u003e\n\u003cli\u003e$1.2T US employer healthcare market (2024 est.)\u003c\/li\u003e\n\u003cli\u003eTarget employers 5,000+ lives\u003c\/li\u003e\n\u003cli\u003ePotential 5-10% specialty-cost savings in 12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/padapting\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolent poised to capture MA and behavioral health upside with AI-driven margin lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare Advantage growth (30.7M enrollees, +7% in 2024) and CMS Star pressure favor Evolent's value‑based platform; FY2024 services revenue $36 PMPM and company revenue $1.6B. AI\/admin automation could cut costs ~20% (McKinsey) and add $16-32M EBITDA (1-2% margin lift). Behavioral health ($240B market) and self‑insured employers (61% of workers) offer expansion and TAM upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMA enrollees\u003c\/td\u003e\n\u003ctd\u003e30.7M (+7%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices rev\u003c\/td\u003e\n\u003ctd\u003e$36 PMPM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany rev\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBehavioral market\u003c\/td\u003e\n\u003ctd\u003e$240B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelf‑insured\u003c\/td\u003e\n\u003ctd\u003e61%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Industry Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvolent faces fierce competition from well-capitalized rivals like Optum (UnitedHealth Group), which reported $156.9B revenue in 2024, and nimble health‑tech startups raising over $8.2B in 2024, threatening Evolent's share in value‑based care.\u003c\/p\u003e\n\u003cp\u003eRivals with deeper pockets or niche platforms can undercut pricing or scale faster, pressuring Evolent's 2024 gross margin of ~18% and contributing to slower client wins.\u003c\/p\u003e\n\u003cp\u003eOngoing product innovation and price competition could erode margins and extend sales cycles, risking slower revenue growth versus peers growing mid‑teens in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe healthcare sector faces frequent federal and state rule changes that can shift reimbursements fast; for example, proposed 2025 Medicare Advantage rate adjustments could affect revenue for value-based care managers like Evolent Health (Evolent Health, NYSE: EVH) which reported $1.3B revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eReforms to the Affordable Care Act, Medicaid funding cuts, or a 1-3% reduction in MA benchmarks would hit client margins and utilization projections.\u003c\/p\u003e\n\u003cp\u003eStaying compliant raises operating costs; Evolent disclosed $95M in selling, general, and admin expenses tied to regulatory activities in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayor Consolidation Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing consolidation among US health insurers (top 10 plans now cover ~50% of lives vs ~42% in 2018) shrinks Evolent Health's pool of large clients and raises customer-concentration risk; mergers often prompt vendor rationalization, and a 2023 McKinsey survey found 38% of merged plans cut external vendor contracts within 12 months, increasing the chance Evolent could be replaced by competitors or in‑house platforms and pressure revenue predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCybersecurity and Data Privacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEvolent handles large volumes of protected health information, making it a prime target: healthcare accounted for 41% of reported breaches by industry in 2023, and the average healthcare breach cost was $11.59M in 2023 (IBM). A major incident could trigger multi‑million dollar fines, class actions, and partner\/patient trust loss that could dent revenue and margins. Continuous investment in security-often \u0026gt;1% of revenue for large health IT firms-is mandatory and recurring.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHealthcare = 41% of breaches (2023)\u003c\/li\u003e\n\u003cli\u003eAverage breach cost $11.59M (IBM, 2023)\u003c\/li\u003e\n\u003cli\u003ePotential multi‑million fines and litigation\u003c\/li\u003e\n\u003cli\u003eSecurity spend often \u0026gt;1% of revenue, recurring\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Downturn Impacts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa broader economic recession could push us unemployment above in risking loss of employer-sponsored coverage and shrinking evolent health managed lives revenue base.\u003e\n\u003cphealth plans under stress become price-sensitive pressuring evolent to accept deeper discounts that compress contract margins medical cost trends and tighter rate negotiations amplify this.\u003e\n\u003cpmacroeconomic instability-higher interest rates and slower elective care-threatens growth trajectory contract profitability especially given evolent reliance on scale multi-year deals.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUnemployment rising to 6%+ reduces covered lives\u003c\/li\u003e\n\u003cli\u003ePlans demand steeper discounts; margin pressure\u003c\/li\u003e\n\u003cli\u003eInterest rates and reduced elective care slow growth\u003c\/li\u003e\n\u003cli\u003eMulti-year contract exposure raises revenue risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmacroeconomic\u003e\u003c\/phealth\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolent under siege: big rivals, funding surge, consolidation, cyber \u0026amp; macro risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvolent faces margin pressure from giants like Optum ($156.9B revenue 2024) and $8.2B+ in 2024 health‑tech funding, regulatory shifts (possible 2025 MA rate cuts), consolidation (top‑10 plans cover ~50% lives), cyber risk (healthcare 41% of breaches; $11.59M avg cost 2023), and macro downside (unemployment spike to 6%+ cuts covered lives).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetition\u003c\/td\u003e\n\u003ctd\u003eOptum $156.9B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003e$8.2B startups (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidation\u003c\/td\u003e\n\u003ctd\u003eTop‑10 plans ~50% lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreaches\u003c\/td\u003e\n\u003ctd\u003e41% of breaches; $11.59M avg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53678559986006,"sku":"evolenthealth-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/evolenthealth-swot-analysis.webp?v=1778883416","url":"https:\/\/balancedscorecardexamples.com\/products\/evolenthealth-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}